As the population ages, the prevalence of diastolic dysfunction and heart failure with preserved ejection fraction is rising. The presentation and management of these patients is increasing in frequency and requires an understanding of its pathophysiology, diagnostic methodology, as well as modern therapy for optimal outcome. This review will discuss the mechanisms, clinical stages, diagnostic grading, and therapeutic options for the management of diastolic dysfunction. submit your manuscript | www.dovepress.com
Dovepress
Dovepress
118Tawil and Gelzinis coronary disease, but are more likely to have hypertension, obesity, and metabolic syndrome. 5
EpidemiologyIn the general population, the prevalence of DD ranges from 21.2% to 27.3%, 6,7 while the prevalence of HFPEF ranges from 1.1% to 1.5%. 8 If left untreated, ~12.2% of patients with DD will progress to overt heart failure. Risk factors for the progression to HFPEF include advanced age and an increased transmitral E to tissue Doppler e′ (E/E′) ratio. 6 Risk factors for the development of HFPEF include hypertension, advanced age, female sex, African-American race, and the presence of the metabolic syndrome. 9 Other comorbidities associated in HFPEF include atrial fibrillation (AF), sleep apnea, chronic obstructive pulmonary disease, renal dysfunction, dyslipidemia, systemic inflammatory diseases, such as rheumatoid arthritis, and certain medications, including antineoplastic agents. 10